Skip to main content

Table 1 Patient demographics and baseline characteristics between group A and group B and between group C and group D

From: Enhanced therapeutic effects of umbilical cord mesenchymal stem cells after prolonged treatment for HBV-related liver failure and liver cirrhosis

Factors Liver failure Liver cirrhosis
Group A Group B P value Group C Group D P value
Sex (M/F) 34/3 22/5 0.266 26/5 23/5 1.000
Age (years) 40 (35–46.5) 42 (33–50) 0.581 47.5 (37.5–56.5) 44 (35–60) 0.665
ALT (U/L) 88 (46.5–312) 77 (46–336) 0.703 48 (23.25–75.75) 42.5 (25.25–89) 0.716
AST (U/L) 109 (68–173.5) 103 (68–147) 0.760 73 (45.25–131.5) 65 (47.5–92) 0.268
TBIL (mmol/L) 486 (346–550.5) 381 (219–495) 0.053 415 (85.25–488.5) 149 (75.7–306.75) 0.027
PTA 35 (25.5–40.5) 34 (31–47) 0.438 40.5 (29.75–53) 44.5 (34.75–59.25) 0.161
MELD 78 (76.5–81) 77 (75–82) 0.411 76 (73–78) 72 (67.75–76) 0.005
  1. ALT alanine aminotransferase, AST glutamic-oxaloacetic transaminase, TBIL total bilirubin, PTA prothrombin time activity, MELD model for end-stage liver disease